Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076986 · ClinicalTrials.gov registry record · Phase 3
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
A Phase 3 study, sponsored by INSYS Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00076986 is a Phase 3 study that has completed, run by INSYS Therapeutics. The registered enrollment target is 300 participants.
The verdict
NCT00076986, a Phase 3 study, has completed, sponsored by INSYS Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following surgical tumor removal in the treatment of first recurrence of glioblastoma multiforme.
Interventions
- DRUG IL13-PE38QQR
- PROCEDURE surgery and catheter placement (2 procedures)
- DRUG prolifespan 20 with carmustine implant (GLIADEL® Wafer)
- PROCEDURE surgery and wafer placement (1 procedure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076986
The ClinicalTrials.gov registry entry for NCT00076986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is INSYS Therapeutics, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which IL13-PE38QQR is the first listed.
NCT00076986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076986 about?
NCT00076986 is a clinical study titled "The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme". The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following surgical tumor removal in the treatment of first recurrence of glioblastoma m...
What is the current status of trial NCT00076986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00076986?
The interventions under investigation include: IL13-PE38QQR (DRUG), surgery and catheter placement (2 procedures) (PROCEDURE), prolifespan 20 with carmustine implant (GLIADEL® Wafer) (DRUG), surgery and wafer placement (1 procedure) (PROCEDURE).
Who is sponsoring clinical trial NCT00076986?
This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.